Home » MIV THERAPEUTICS' BREAKTHROUGH VASCULAR STENT COATING TECHNOLOGY RECEIVES KEY INDEPENDENT ENDORSEMENT IN NEW SCIENTIFIC STUDY
MIV THERAPEUTICS' BREAKTHROUGH VASCULAR STENT COATING TECHNOLOGY RECEIVES KEY INDEPENDENT ENDORSEMENT IN NEW SCIENTIFIC STUDY
MIV Therapeutics , a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced June 5 that the safety and biocompatibility of its proprietary Hydroxyapatite (HAp) vascular stent coating technology has received pivotal independent confirmation in a new study conducted by a team of researchers in Italy and published in the renowned Journal of Biomedical Materials Research, a prestigious international journal of materials sciences.
MIV
Therapeutics
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May